Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

Abstract

Efficacy and safety of nab-paclitaxel plus gemcitabine have not been clarified in Japanese patients with metastatic pancreatic cancer. No pharmacokinetic profile of co-administration of nab-paclitaxel and gemcitabine has been reported. We conducted a phase I/II study of the efficacy, safety, and pharmacokinetics in Japanese patients with metastatic pancreatic cancer. The patients were administered 125 mg/m2 nab-paclitaxel followed by 1000 mg/m2 gemcitabine on day 1, 8, and 15 every 4 weeks. Treatment was continued until disease progression, unacceptable adverse events, or withdrawal of consent, whichever occurred first. The primary endpoints were tolerability in phase I and overall response rate according to RECIST in phase II. A total of 34 patients were enrolled. At the time of 1-year follow-up analysis since the last patient enrollment, the objective response rate by independent review committee was 58.8 % (20 of 34 patients; 95 % confidence interval [CI], 40.7–75.4 %). The median progression-free survival and median overall survival were 6.5 months (95 % CI, 5.1–8.3) and 13.5 months (95 % CI, 10.6—not reached), respectively. Main adverse drug reactions of grade 3 or higher were neutropenia (70.6 %), leukopenia (55.9 %), anemia (14.7 %), lymphocytopenia (14.7 %), thrombocytopenia (14.7 %), and peripheral sensory neuropathy (11.8 %). There were no treatment-related deaths and no marked differences in pharmacokinetics of combined paclitaxel and gemcitabine in historical comparison between co-administration and monotherapies. Nab-paclitaxel plus gemcitabine regimen showed highly promising efficacy with manageable safety profile under careful observation and with appropriate supportive care in Japanese patients with metastatic pancreatic cancer. JapicCTI-121987.

DOI: 10.1007/s00280-016-2972-3

6 Figures and Tables

Statistics

0500100015002017
Citations per Year

525 Citations

Semantic Scholar estimates that this publication has 525 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ueno2016PhaseIS, title={Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer}, author={Hideki Ueno and M. Ikeda and Makoto Ueno and Nobumasa Mizuno and Tatsuya Ioka and Yasushi Omuro and Takako Eguchi Nakajima and Junji Furuse}, journal={Cancer Chemotherapy and Pharmacology}, year={2016}, volume={77}, pages={595-603} }